{"id":"dexchlorpheniramine-or-diphenhydramine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Drowsiness/sedation"},{"rate":"10-20","effect":"Dry mouth"},{"rate":"5-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Anticholinergic effects (urinary retention, constipation)"}]},"_chembl":{"chemblId":"CHEMBL1200927","moleculeType":"Small molecule","molecularWeight":"390.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both dexchlorpheniramine and diphenhydramine are first-generation antihistamines that competitively antagonize H1 histamine receptors on target tissues. This prevents histamine-mediated effects such as itching, urticaria, angioedema, and other allergic symptoms. These agents also cross the blood-brain barrier, producing sedation as a common side effect.","oneSentence":"Blocks histamine H1 receptors to reduce allergic and inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:42.911Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Urticaria and pruritus"},{"name":"Allergic reactions"},{"name":"Motion sickness (diphenhydramine)"},{"name":"Sleep aid (diphenhydramine)"}]},"trialDetails":[{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":"Circulating Tumor Cell, Metastatic Prostate Cancer","enrollment":140},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Prostate Cancer","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4711,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexchlorpheniramine or Diphenhydramine","genericName":"Dexchlorpheniramine or Diphenhydramine","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks histamine H1 receptors to reduce allergic and inflammatory responses. Used for Allergic rhinitis, Urticaria and pruritus, Allergic reactions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}